title: Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration.
abstract: OBJECTIVE
  Information regarding the ideal length of hot flash trials is scarce. In the literature, hot flash trial durations have commonly varied from 4 to 12 weeks. This article is devoted to providing scientific data to better ascertain how long it is necessary to conduct hot flash trials with newer centrally acting agents.
  
  
  METHODS
  Individual participant data were collected from all known published, through December 2007, randomized, placebo-controlled, double-blinded clinical trials regarding the use of newer antidepressants and gabapentin for hot flash relief. Trials that studied periods longer than 4 weeks were included for this project. Profile analysis was applied to the hot flash activity longitudinal data for each study individually, allowing a comparison of data collected for 6 to 12 treatment weeks versus data collected for only 4 treatment weeks.
  
  
  RESULTS
  Ten studies were identified, five of them fulfilled the eligibility criteria for this investigation, three evaluating gabapentin, and two newer antidepressants. Flatness tests from a profile analysis did not provide any evidence that hot flash activity increased or decreased between week 4 and time periods up to 12 weeks.
  
  
  CONCLUSIONS
  Changes in hot flash scores from newer antidepressants and gabapentin are apparent within 4 weeks of therapy. Available data indicate that hot flash treatment efficacy, compared with that of placebo, remains stable for up to 12 weeks of follow-up.
authors.affiliation: Mayo Clinic, Rochester, MN, USA. cloprinzi@mayo.edu
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: Brent
authors.initials: B
authors.lastname: Diekmann
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Novotny
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D003625:Data Collection; D004311:Double-Blind Method; D000077206:Gabapentin; D017408:Guidelines as Topic; D019584:Hot Flashes / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012107:Research Design / Q000592:standards*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000928:Antidepressive Agents; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin